Checkpoint Therapeutics Inc. (CKPT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
CKPT Chart
Checkpoint Therapeutics shares pop on acquisition by Sun Pharma
Checkpoint Therapeutics (NASDAQ:CKPT) shares added more than 60% after it was revealed the immunology and targeted oncology firm will be acquired by Sun Pharmaceutical Industries. Under the agreement, Sun Pharma will acquire Checkpoint for $4.10 per share in cash, representing up to $355 million in upfront payments.
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval
Checkpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor reactions, Unloxcyt's potential $1.6B peak sales and competitive pricing could make it a transformative player in the cSCC market. Risks include high competition, commercialization costs, and potential IP challenges, but Checkpoint's strategic partnerships and marketing are crucial for success.
Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date
Checkpoint Therapeutics, Inc.'s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th is crucial, with potential FDA approval driving significant market growth and revenue projections. Despite competitive pressures and financial risks, cosibelimab's unique mechanism and strong IP position offer substantial market opportunities in cSCC and beyond.
Checkpoint Therapeutics Inc. (CKPT) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Checkpoint Therapeutics Inc. Profile
| - Industry | - Sector | James F. Oliviero III, CEO | NASDAQ (CM) Exchange | 162828107 CUSIP |
| US Country | 24 Employees | - Last Dividend | 6 Dec 2022 Last Split | 26 Jun 2017 IPO Date |
Overview
Checkpoint Therapeutics, Inc., established in 2014 and operating out of Waltham, Massachusetts, is a pioneer in the field of immunotherapy and targeted oncology. The company dedicates itself to developing and commercializing innovative treatments for patients suffering from solid tumor cancers both in the United States and internationally. As a clinical-stage entity, Checkpoint Therapeutics strategically focuses on acquiring, developing, and commercializing novel therapeutics designed to improve the lives of those battling cancer. It functions under the umbrella of Fortress Biotech, Inc., serving as a testament to its robust backing and commitment to advancing cancer treatment options.
Products and Services
The company's portfolio reflects its dedication to offering a broad spectrum of solutions aimed at addressing various cancer types through advanced clinical trials and innovative research. Below are the key product candidates spearheaded by Checkpoint Therapeutics:
- Cosibelimab: Currently in Phase 1 clinical trials, Cosibelimab is a leading antibody product candidate focused on treating patients with select recurrent or metastatic cancers. This research endeavors to bring forth a potent solution for cancers that have previously shown resistance to standard treatments.
- CK-302: This product candidate is in the preclinical trial phase, aiming at developing effective treatments for hematological malignancies and solid tumors. It represents Checkpoint Therapeutics' commitment to expanding its therapeutic offerings beyond solely solid tumor cancers.
- Olafertinib: Progressing through Phase 3 clinical trials, Olafertinib targets adult patients with metastatic non-small cell lung cancer. This drug signifies a major stride in tackling one of the most common and aggressive forms of lung cancer, promising a new hope for patients with advanced disease stages.
- CK-103: Aimed at treating various advanced and metastatic solid tumor cancers, CK-103 is under development to address a wide range of solid tumor types. Its versatility and potential efficacy mark a significant contribution to the portfolio of cancer treatment options.
- Anti-Carbonic Anhydrase IX (CAIX) antibody: In the preclinical trial phase, this product candidate is designed to target CAIX expressing cells and eliminate them through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. This innovative approach holds the promise of effectively targeting and eradicating cancer cells with minimal harm to normal tissues.
Checkpoint Therapeutics has established pivotal licensing and collaboration agreements to fortify its product development and commercialization strategies. Partnerships with Adimab, LLC for Cosibelimab, NeuPharma, Inc. for Olafertinib, and Jubilant Biosys Limited for the development of novel compounds targeting BET bromodomains underscore the company's dynamic approach to revolutionizing cancer treatment through cutting-edge research and collaboration.
